A Phase 2A Randomized, Placebo Controlled, Double Blind Study of the Protective Effects of EPI-743 (Vincerinone) on Noise-Induced Hearing Loss

Trial Profile

A Phase 2A Randomized, Placebo Controlled, Double Blind Study of the Protective Effects of EPI-743 (Vincerinone) on Noise-Induced Hearing Loss

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Vatiquinone (Primary)
  • Indications Noise-induced hearing loss
  • Focus Therapeutic Use
  • Sponsors Edison Pharmaceuticals
  • Most Recent Events

    • 18 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jan 2016 Planned End Date changed from 1 Sep 2015 to 1 Feb 2016, according to ClinicalTrials.gov record.
    • 19 Jan 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Nov 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top